Abstract:Parkin, a ring-between-ring-type E3 ubiquitin ligase, first shown to play a critical role in autosomal recessive juvenile Parkinsonism, has recently emerged as a key player in cancer biology. Parkin is now known to serve as a tumor suppressor, and its deregulation frequently promotes tumorigenesis. In this issue of the JCI , Perego et al. expand that role by showing that Parkin expression stimulated an interferon (IFN) response to modulate CD8 + T cell activity. These findings suggest that, in addition to directly inhibiting tumor progression, Parkin enhances antitumor immune responses, highlighting it as a promising therapeutic target for cancer treatment.

Parkin paves the path to antitumor immunity: Expanding Parkin's role as a tumor suppressor